pipeline

pipeline
HY209
Indication Optimization Pre-clinical ADMET/CMC Ph Ⅰ Ph Ⅱ
NuGel® Atopic Dermatitis
TO
NuSepin® COVID-19
IV
Oral HY209
  • ˙Long COVID
  • ˙Alzheimer’s disease
  • ˙Ulcerative colitis
  • ˙NASH
  • ˙Atopic dermatitis
PO
HY209
Analogues
Chronic inflammation
Nanobody
Indication Optimization Pre-clinical ADMET/CMC Ph Ⅰ Ph Ⅱ
Saviximab®(Anti-SARS-CoV-2) SARS-CoV-2
IV
Papiliximab® (Anti-PD-L1xCD47) Oncology
IV
Undisclosed Oncology
IV

R&D collaboration : Dong-A ST
R&D collaboration : Korea Research Institute of Bioscience and Biotechnology